Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Conclusion: Acalabrutinib monotherapy produced high ORR in R/R and high-risk TN CLL, with an acceptable safety profile. The study was not designed to detect a statistically significant difference in clinical outcomes between the dosing groups. Near complete target coverage (>95%) was more rapidly achieved with 100 mg BID than 200 mg QD dosing in the lymph node and peripheral blood.DisclosuresNierman: National Institutes of Health: Employment. Covey: Acerta Pharma: Employment; AstraZeneca: Equity Ownership. Hamdy: Acerta Pharma: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: various patents for ACP-196. Izumi: Acerta Pharma: Employment, Equity Ownership, Patents & Royalties: Acerta Pharma, various patents for ACP-196. Liu: Acerta Pharma: Employment. Patel: Acerta Pharma: Employment, Equity Ownership. Wiestner: Pharmacyclics LLC, an AbbVie Company: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Sun, C. C., Nierman, P., Ahn, I. E., Valdez, J., Lotter, J., Soto, S., Herman, S. E. M., Covey, T., Hamdy, A., Izumi, R., Liu, D., Patel, P., Wiestner, A. Tags: 642. CLL: Therapy, excluding Transplantation: Poster III Source Type: research